Ann D. Kwong
Hoofd Techniek/Wetenschap/O&O bij PARDES BIOSCIENCES, INC.
Oorsprong van het eerstegraads netwerk van Ann D. Kwong
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 6 | |
Trek Therapeutics PBC
 Trek Therapeutics PBC Pharmaceuticals: MajorHealth Technology Trek Therapeutics PBC is a for-profit company based in Cambridge, MA. The private company's mission is to develop medicines to treat infectious diseases and make them available to populations in need. The founders of the company, Jerome B. Zeldis and Ann D. Kwong, have collectively participated in developing seven approved antiviral drugs. The company aims to profitably develop safe, novel medicines for infectious diseases at affordable prices. Ann D. Kwong has been the CEO since incorporation.
4
| Private Company | Pharmaceuticals: Major | 4 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Ann D. Kwong via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| CELGENE | Biotechnology | Chief Tech/Sci/R&D Officer | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal | |
| GILEAD SCIENCES, INC. | Biotechnology | Investor Relations Contact | |
| SOLIGENIX, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| LIGAND PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Public Communications Contact | |
| CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
Foresite Life Sciences Corp.
 Foresite Life Sciences Corp. Financial ConglomeratesFinance Foresite Life Sciences Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded in January 2021 and is headquartered in San Francisco, CA. | Financial Conglomerates | Chief Executive Officer Director of Finance/CFO | |
Foresite Capital Management LLC
 Foresite Capital Management LLC Investment ManagersFinance Foresite Capital Management LLC (Foresite Capital) is a private equity firm founded in 2010 by James Tananbaum. The firm is headquartered in San Francisco. | Investment Managers | Chief Executive Officer Director of Finance/CFO | |
| Harvard Medical School | College/University | Doctorate Degree Corporate Officer/Principal | |
| Brown University | College/University | Graduate Degree Undergraduate Degree | |
| Yale University | College/University | Corporate Officer/Principal Doctorate Degree | |
Etubics Corp.
 Etubics Corp. BiotechnologyHealth Technology Etubics Corp. develops commercial prophylactic vaccines and immunotherapy products. It offers proprietary immunization platform technology called the etubics platform that develops therapeutic vaccines for colon and breast cancers and preventative vaccines for H1N1 Influenza and HIV. The company was founded by Frank R. Jones in 2003 and is headquartered in Seattle, WA. | Biotechnology | Director/Board Member | |
| BEYOND AIR, INC. | Medical Specialties | Director/Board Member | |
| CLARITAS PHARMACEUTICALS, INC. | Pharmaceuticals: Other | Director/Board Member | |
| Weill Cornell Medical College | College/University | Corporate Officer/Principal | |
| SORRENTO THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| METASTAT, INC. | Electrical Products | Chairman | |
| Robert Wood Johnson Medical School | College/University | Corporate Officer/Principal | |
Beyond Air Ltd.
 Beyond Air Ltd. BiotechnologyHealth Technology Beyond Air, Ltd. is a clinical-stage medical device and biopharmaceutical company engaging in the development of nitric oxide generator and delivery system that uses nitric oxide generated from ambient air and delivers precise amounts of nitric oxide to the lungs for the potential treatment of respiratory and other diseases. The company was founded by Yossef Av-Gay, Amir Avniel, and David Greenberg in May 2011 and is headquartered in Rehovot, Israel. | Biotechnology | Director/Board Member | |
Immodulon Therapeutics Ltd.
 Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
| University of California, Davis | College/University | Corporate Officer/Principal | |
| PTC Corp. | Director/Board Member | ||
The Arthritis Foundation
 The Arthritis Foundation Miscellaneous Commercial ServicesCommercial Services Arthritis Foundation provides funds research, advocacy and support services for various kinds of arthritis and related diseases. It offers programs and services including aquatic programs, information about treatment breakthroughs, exercise tips for people with the disease and pain management information. Arthritis Foundation is located in Atlanta, GA. | Miscellaneous Commercial Services | Director/Board Member | |
| PTC THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| Semorex, Inc. | Director/Board Member | ||
Prospect Venture Partners
 Prospect Venture Partners Investment ManagersFinance Prospect Venture Partners (Prospect Venture Partners) is a venture capital firm founded in 1997 by Alexander E. Barkas and David Schnell. The firm is headquartered in Palo Alto, California. | Investment Managers | Private Equity Investor | |
Celularity, Inc. (United States)
 Celularity, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Celularity, Inc. engages in biotechnology company. The firm focuses on the study of placenta. The company was founded in Robert Joseph Hariri Gordon and Peter H. Diamandis in 2016 and is headquartered in Florham Park, NJ. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
| CELLDEX THERAPEUTICS, INC. | Medical/Nursing Services | Director/Board Member | |
| IKENA ONCOLOGY, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| University of Toronto | College/University | Undergraduate Degree | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree | |
| University of California | College/University | Undergraduate Degree | |
| Kellogg School of Management | College/University | Masters Business Admin | |
| Loyola University New Orleans | College/University | Undergraduate Degree | |
| VIR BIOTECHNOLOGY, INC. | Biotechnology | Investor Relations Contact |
Statistieken
Internationaal
| Verenigde Staten | 42 |
| Israël | 2 |
| Verenigd Koninkrijk | 2 |
| Noorwegen | 2 |
| Canada | 2 |
Sectoraal
| Health Technology | 21 |
| Consumer Services | 12 |
| Finance | 7 |
| Commercial Services | 4 |
| Producer Manufacturing | 2 |
Operationeel
| Director/Board Member | 78 |
| Corporate Officer/Principal | 23 |
| Independent Dir/Board Member | 13 |
| Founder | 10 |
| Chief Tech/Sci/R&D Officer | 9 |
Sterkste connecties
| Insiders | |
|---|---|
| James Tananbaum | 60 |
| Jerome Zeldis | 38 |
| Dennis Ryan | 11 |
| Keith Brownlie | 10 |
| Valdas Jurkauskas | 7 |
| Patrick O’Brien | 6 |
| Sean P. Brusky | 5 |
| Dave Kuo | 3 |
| Murray McKinnell | 1 |
| Charles M. Rice | 1 |
- Beurs
- Insiders
- Ann D. Kwong
- Bedrijfsconnecties
